CREO MEDICAL GROUP PLC Financials Creo Medical Group PLC
Equities
CREO
GB00BZ1BLL44
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.5 GBX | -0.70% |
|
+7.58% | -22.82% |
| May. 15 | Creo Medical on track to break even next year on strong 2023 results | AN |
| May. 15 | Creo Medical Group PLC Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 239.8 | 272.2 | 306.3 | 265.4 | 45.08 | 124.6 | 124.6 | - |
| Enterprise Value (EV) 1 | 195.2 | 191.1 | 273.6 | 232.4 | 43.67 | 160.2 | 124.4 | 118.7 |
| P/E ratio | -12.4 x | -13.9 x | -14.9 x | -9.93 x | -1.68 x | -6.57 x | -9.17 x | -56.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 20,207 x | 32.5 x | 10.5 x | 1.66 x | 5.2 x | 3.09 x | 2.24 x |
| EV / Revenue | - | 14,190 x | 29 x | 9.24 x | 1.61 x | 5.2 x | 3.08 x | 2.13 x |
| EV / EBITDA | -11.4 x | -10.5 x | -12.5 x | -8.5 x | -1.98 x | -9.1 x | -9.4 x | -94.5 x |
| EV / FCF | - | - | - | -7.3 x | -1.55 x | -6.18 x | -14.5 x | 148 x |
| FCF Yield | - | - | - | -13.7% | -64.5% | -16.2% | -6.91% | 0.67% |
| Price to Book | - | - | - | - | - | 1.92 x | 2.27 x | 2.3 x |
| Nbr of stocks (in thousands) | 120,495 | 150,379 | 157,891 | 178,099 | 178,546 | 348,476 | 348,476 | - |
| Reference price 2 | 1.990 | 1.810 | 1.940 | 1.490 | 0.2525 | 0.3575 | 0.3575 | 0.3575 |
| Announcement Date | 4/5/19 | 5/7/20 | 6/4/21 | 5/23/22 | 4/26/23 | 5/15/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.0135 | 9.429 | 25.16 | 27.17 | 30.8 | 40.37 | 55.62 |
| EBITDA 1 | -17.17 | -18.23 | -21.89 | -27.34 | -22.08 | -17.6 | -13.24 | -1.256 |
| EBIT 1 | -17.66 | -18.88 | -23.48 | -29.91 | -30.76 | -24.8 | -16.26 | -4.439 |
| Operating Margin | - | -140,129.03% | -249.07% | -118.86% | -113.2% | -80.52% | -40.28% | -7.98% |
| Earnings before Tax (EBT) 1 | -17.58 | -18.62 | -23.46 | -30.34 | -30.98 | -24.5 | -16.56 | -4.892 |
| Net income 1 | -14.81 | -15.91 | -20.32 | -24.6 | -26.94 | -21.72 | -14.08 | -2.224 |
| Net margin | - | -118,122.87% | -215.46% | -97.75% | -99.14% | -70.52% | -34.86% | -4% |
| EPS 2 | -0.1600 | -0.1300 | -0.1300 | -0.1500 | -0.1500 | -0.0700 | -0.0390 | -0.006280 |
| Free Cash Flow 1 | - | - | - | -31.84 | -28.16 | -16.6 | -8.6 | 0.8 |
| FCF margin | - | - | - | -126.54% | -103.66% | -51.79% | -21.3% | 1.44% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 4/5/19 | 5/7/20 | 6/4/21 | 5/23/22 | 4/26/23 | 5/15/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 | 2023 S1 |
|---|---|---|
| Net sales | - | - |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income 1 | -13.43 | -11.6 |
| Net margin | - | - |
| EPS 2 | -0.0700 | -0.0400 |
| Dividend per Share | - | - |
| Announcement Date | 9/9/22 | 9/12/23 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 44.6 | 81 | 32.7 | 33 | 1.41 | 22 | 0.13 | 5.85 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -31.8 | -28.2 | -16.6 | -8.6 | 0.8 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | -29.3% | -18.2% | -2% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | -20.3% | -11.8% | -0.79% |
| Assets 1 | - | - | - | - | - | 90.75 | 119.5 | 280.8 |
| Book Value Per Share 2 | - | - | - | - | - | 0.1900 | 0.1600 | 0.1600 |
| Cash Flow per Share 2 | - | - | - | - | - | -0.0400 | -0.0300 | 0 |
| Capex 1 | 1.08 | 0.48 | 0.48 | 5.98 | 3.18 | 1.58 | 1.48 | 1.58 |
| Capex / Sales | - | 3,593.24% | 5.14% | 23.75% | 11.7% | 4.94% | 3.68% | 2.84% |
| Announcement Date | 4/5/19 | 5/7/20 | 6/4/21 | 5/23/22 | 4/26/23 | 5/15/24 | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3575
GBP
Average target price
0.895
GBP
Spread / Average Target
+150.35%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -22.82% | 159M | |
| +75.28% | 12.54B | |
| -20.90% | 7.71B | |
| +8.01% | 6.72B | |
| +12.49% | 5.38B | |
| +37.02% | 4.89B | |
| -17.37% | 4.71B | |
| -25.08% | 3.75B | |
| -26.57% | 2.77B | |
| +58.74% | 2.55B |
- Stock Market
- Equities
- CREO Stock
- Financials Creo Medical Group PLC
